Hematologic Oncology

In the phase II CLOVER-1 trial, investigators are evaluating whether CLR 131 will be an effective option for patients with difficult-to-treat relapsed or refractory B-cell lymphomas.

Alexander Edward Perl, MD, MS, discusses advancements in acute myeloid leukemia treatment and future approaches in the field.

Sunita Nasta, MD, discusses exciting updates in follicular lymphoma, diffuse large B-cell lymphoma, and T-cell lymphoma and the impact they will have on the upfront and relapsed/refractory paradigms.

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in treating patients with myelofibrosis.

Faculty from the George Washington Cancer Center to shed light on some of the current and future research efforts being made at their institution.

Imad Tabbara, MD, discusses the role of minimal residual disease testing in multiple myeloma, acute lymphoblastic leukemia, and acute myeloid leukemia, as well as emerging regimens in all 3 malignancies that are changing standards of care.

John F. DiPersio, MD, PhD, discusses the current state of CAR T-cell therapy, dual affinity re-targeting, bi-specific T-cell engagers, and antibody-drug conjugates for acute myeloid leukemia treatment.

We traveled to Seattle, Washington, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Seattle Cancer Care Alliance faculty.

The FDA has awarded 12 new research grants that together total more than $15 million, to enhance the development of medical products for patients with rare diseases, including acute myeloid leukemia and gastrointestinal stromal tumor, among others.

Leading oncology experts at the University of California, Los Angeles share the pivotal research being conducted at their institution.

Alexander E. Perl, MD, MS, discusses how to assess what therapy is best for patients with acute myeloid leukemia.

Although clonal hematopoiesis of indeterminate potential is recognized as a risk factor for developing hematological neoplasms, a growing body of evidence points to its potential significance in broader clinical scenarios.

John M. Timmerman, MD, discusses recent developments made in the treatment of patients with Hodgkin lymphoma.

Jasmine M. Zain, MD, discusses the phase III ECHELON-2 trial and the ongoing work being done in peripheral T-cell lymphoma and other T-cell lymphomas.

Imad Tabbara, MD, discusses the expansion of treatment options for patients with acute myeloid leukemia.

Two clinical trials evaluating blinatumomab compared with chemotherapy in pediatric patients with acute lymphoblastic leukemia were stopped early due to treatment benefit with the bispecific T-cell engager.

John M. Timmerman, MD, discusses the research being conducted across the spectrum of Hodgkin and non-Hodgkin lymphoma.

Matthew G. Mei, MD, discusses current considerations in the frontline management of advanced-stage Hodgkin lymphoma as well as ongoing investigations with checkpoint inhibitors and cellular-based therapy.

Kanwarpal S. Kahlon, MD, discusses current treatment options for patients with aplastic anemia, immune thrombocytopenic purpura, and thrombotic thrombocytopenic purpura, as well as future research for the field.

The addition of the antibody-drug conjugate brentuximab vedotin and the PD-1 inhibitor nivolumab to chemotherapy in patients with stage I/II Hodgkin lymphoma is under investigation in an ongoing phase II trial (NCT03233347).

Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of gilteritinib as a single agent for the treatment of adult patients with relapsed/refractory acute myeloid leukemia who have FLT3 mutations.

Gary J. Schiller, MD, discusses therapeutic advances, the importance of genomic testing, and other agents in the pipeline for acute myeloid leukemia.

Christopher S. Seet, MD, PhD, discusses elements of treatment discontinuation in chronic myeloid leukemia.

Christopher S. Seet, MD, PhD, hematologist and oncologist, UCLA, discusses aspects of treatment discontinuation in chronic myeloid leukemia (CML).